References
- Mattox AK, Bettegowda C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B. Applications of liquid biopsies for cancer. Sci. Transl. Med. 11(507), eaay1984 (2019).
- Cohen JD, Li L, Wang Y et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359(6378), 926–930 (2018).
- Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann. Oncol. 32(9), 1167–1177 (2021).
- Lennon AM, Buchanan AH, Kinde I et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 369(6499), eabb9601 (2020).
- Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum. Genomics 13(1), 34 (2019).
- US Preventive Services Task Force. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325(10), 962–970 (2021).
- US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325(19), 1965–1977 (2021).
- US Preventive Services Task Force. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 320(7), 674–686 (2018).
- Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann. Intern. Med. 164(4), 279–296 (2016).
- Schrag D, Beer TM, McDonnell CH et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. The Lancet 402(10409), 1251–1260 (2023).
- GRAIL Announces Final Results From the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022. GRAIL, https://grail.com/press-releases/grail-announces-final-results-from-the-pathfinder-multi-cancer-early-detection-screening-study-at-esmo-congress-2022/ ( Accessed 17 July 2023).
- Minasian LM, Pinsky P, Katki HA et al. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. J. Natl Cancer Inst. 115(3), 250–257 (2023).
- Owens L, Gulati R, Etzioni R. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests. Cancer Epidemiol. Biomark Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 31(7), 1298–1304 (2022).
- Trosman JR, Weldon CB, Kurian AW et al. Perspectives of private payers on multicancer early-detection tests: informing research, implementation, and policy. Health Aff. Sch. 1(1), qxad005 (2023).
- Selby K, Elwyn G, Volk RJ. Multi-cancer Early Detection Tests, Primary Care, and Shared Decision Making. Ann. Intern. Med. 176(5), 718–720 (2023).
- Ueberroth BE, Marks LA, Borad MJ, Agrwal N. Multicancer Early detection Panels (MCEDs) in the Primary Care Setting. Am. J. Med. 135(7), e145–e149 (2022).
- Davis KV, Hallman MH, DiCarlo M et al. Factors Likely to Affect the Uptake of Genomic Approaches to Cancer Screening in Primary Care: A Scoping Review. J. Pers Med. 12(12), 2044 (2022).
- American Cancer Society. Multi-cancer Early Detection (MCED) Tests. Published 30 June 2022. www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html ( Accessed 14 July 2023).
- National Cancer Institute Division of Cancer Prevention. Questions and Answers about MCD Tests. https://prevention.cancer.gov/major-programs/multi-cancer-detection-mcd-research/questions-and-answers-about-mcd-tests ( Accessed 18 July 2023).
- Prevent Cancer Foundation. Multi-Cancer Early Detection Overview. Published 2023. www.preventcancer.org/multi-cancer-early-detection/overview/ ( Accessed 18 July 2023).
- MCED Consortium. MCED Consortium. www.mced.info ( Accessed 18 July 2023).
- Mercy. Multi-Cancer Early Detection Test. Mercy. Published 2023. www.mercy.net/service/multi-cancer-early-detection-test ( Accessed 18 July 2023).
- GRAIL. Multi-Cancer Early Detection | Patient Overview. Galleri® Test. Published 2023. www.galleri.com/patient ( Accessed 18 July 2023).
- Nadauld LD, Vega CP. What is multicancer early detection screening? In: Early Cancer Detection in Primary Care: Are You Aware of New Blood-Based Multi-Cancer Screening Tools?. Global Education Group and Integritas Communications (2022).28 https://play.google.com/books/reader?id=5WlsEAAAQBAJ&pg=GBS.PP1&hl=en ( Accessed 27 July 2023).
- Prevent Cancer Foundation. When it comes to cancer, we need time on our side. Published online June 2022. www.preventcancer.org/wp-content/uploads/2022/06/MCED-Infographic-Letter-for-print.pdf ( Accessed July 27, 2023).
- Shoemaker SJ, Wolf MS, Brach C. Development of the Patient Education Materials Assessment Tool (PEMAT): a new measure of understandability and actionability for print and audiovisual patient information. Patient Educ. Couns. 96(3), 395–403 (2014).
- Shoemaker SJ, Wolf MS, Brach C. The Patient Education Materials Assessment Tool (PEMAT) and User's Guide. Agency for Healthcare Research and Quality. Published November 2020. www.ahrq.gov/health-literacy/patient-education/pemat.html ( Accessed 20 July 2023).
- Minasian LM, Pinsky P, Katki HA et al. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility. J. Natl Cancer Inst. 115(3), 250–257 (2023).
- National Cancer Institute Division of Cancer Prevention. Multi-Cancer Detection (MCD) Research. Multi-Cancer Detection (MCD) Research. https://prevention.cancer.gov/major-programs/multi-cancer-detection-mcd-research ( Accessed 2 August 2023).
- National Institutes of Health. Clear communication. National Institutes of Health (NIH). Published 7 July 2021. www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/clear-communication/clear-simple ( Accessed 2 August 2023).
- Centers for Medicare & Medicaid Services. Guidelines for effective writing. Published 15 May 2023. www.cms.gov/outreach-and-education/outreach/writing-guidelines?redirect=/writtenmaterialstoolkit/ ( Accessed 2 August 2023).